Compare PRSO & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | ASBP |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.6M |
| IPO Year | 2001 | N/A |
| Metric | PRSO | ASBP |
|---|---|---|
| Price | $1.18 | $2.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 392.9K | ★ 1.3M |
| Earning Date | 11-10-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,001,000.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $0.52 | $1.66 |
| 52 Week High | $2.37 | $632.00 |
| Indicator | PRSO | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 95.30 |
| Support Level | $0.93 | $0.05 |
| Resistance Level | $1.04 | $0.10 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 88.89 | 95.90 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.